



December 29, 2020

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Enclosed is a Press Release as regards launch of Mycophenolate Mofetil Tablets USP, 500 mg, by the Company, after its alliance partner Concord Biotech Limited received an approval for its ANDA from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS-11973)**

Encl- : a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin launches Mycophenolate Mofetil Tablets USP

Mumbai, Baltimore, December 29, 2020: Lupin Limited (Lupin), global pharmaceutical company, announced today the launch of Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin's alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration.

Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept® Tablets of Roche Palo Alto LLC, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets USP (RLD: CellCept®) had an annual sales of approximately USD 87 million in the U.S. (IQVIA MAT October 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: [www.twitter.com/LupinGlobal](https://twitter.com/LupinGlobal) | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Shweta Munjal Head – Corporate Communications Email: shwetamunjal@lupin.com	Arvind Bothra Head – Investor Relations and M&A Email: arvindbothra@lupin.com	Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com
--	--	--

****Safe Harbor Statement***

CellCept® is a registered trademark of Roche Holdings Inc.